Literature DB >> 9372872

Development of a decision-making tool to predict risk of prostate cancer: the Cancer of the Prostate Risk Index (CAPRI) test.

S A Optenberg1, J Y Clark, M K Brawer, I M Thompson, C R Stein, P Friedrichs.   

Abstract

OBJECTIVES: To provide a simple and reliable clinical prediction for an individual patient's overall risk of cancer at biopsy by deriving an easily implemented test based on a generalizable model. Four variables are analyzed for inclusion in the model: prostate-specific antigen (PSA) level, digital rectal examination (DRE) results, race, and age.
METHODS: Two populations were used to develop and validate the test: a model (n = 633) and an independent, geographically separate, external population (n = 766). Pathology records for patients who underwent prostate biopsy between 1991 and 1995 were reviewed and screened for the presence of PSA and DRE results. Records where age and race could be determined were extracted. Multiple logistic regression was used with an iterative approach to optimize each test factor. The Wald chi-square test, receiver operating characteristic (ROC) curve, and Hosmer-Lemingshaw test were used to evaluate the model's predictive capability in the two populations.
RESULTS: The model and external populations were significantly different for racial mix, PSA level, age, and biopsy detection rate, providing diverse populations to validate the test. Within a combined model, PSA, DRE, race, and age all demonstrated independent capability to predict cancer at biopsy. Predictive power of the overall test was high within the model population (ROC 80.8%), with minimal loss of power in the external population. The test demonstrated no significant lack of fit in either population.
CONCLUSIONS: Within a combined test, PSA, DRE, race, and age all contribute significantly to prediction of prostate cancer at biopsy in an individual patient. The test depicts individual risk in an easily understood, visually provocative manner and should assist the clinician and patient in reaching a decision as to whether biopsy is appropriate.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9372872     DOI: 10.1016/S0090-4295(97)00451-2

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  8 in total

1.  Addressing issues associated with evaluating prediction models for survival endpoints based on the concordance statistic.

Authors:  Ming Wang; Qi Long
Journal:  Biometrics       Date:  2016-01-12       Impact factor: 2.571

2.  A Risk Prediction Model for Sporadic CRC Based on Routine Lab Results.

Authors:  Ben Boursi; Ronac Mamtani; Wei-Ting Hwang; Kevin Haynes; Yu-Xiao Yang
Journal:  Dig Dis Sci       Date:  2016-02-19       Impact factor: 3.199

3.  A comparison of Bayesian and frequentist approaches to incorporating external information for the prediction of prostate cancer risk.

Authors:  Paul J Newcombe; Brian H Reck; Jielin Sun; Greg T Platek; Claudio Verzilli; A Karim Kader; Seong-Tae Kim; Fang-Chi Hsu; Zheng Zhang; S Lilly Zheng; Vincent E Mooser; Lynn D Condreay; Colin F Spraggs; John C Whittaker; Roger S Rittmaster; Jianfeng Xu
Journal:  Genet Epidemiol       Date:  2012-01       Impact factor: 2.135

4.  Integration of magnetic resonance imaging into prostate cancer nomograms.

Authors:  Garrett J Brinkley; Andrew M Fang; Soroush Rais-Bahrami
Journal:  Ther Adv Urol       Date:  2022-05-13

5.  Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone.

Authors:  David J Hernandez; Misop Han; Elizabeth B Humphreys; Leslie A Mangold; Samir S Taneja; Stacy J Childs; Georg Bartsch; Alan W Partin
Journal:  BJU Int       Date:  2008-10-24       Impact factor: 5.588

6.  Nomogram for prediction of prostate cancer with serum prostate specific antigen less than 10 ng/mL.

Authors:  Jae Hyun Ahn; Jeong Zoo Lee; Moon Kee Chung; Hong Koo Ha
Journal:  J Korean Med Sci       Date:  2014-02-27       Impact factor: 2.153

7.  Development of a risk score for colorectal cancer in Chinese males: A prospective cohort study.

Authors:  Lanwei Guo; Hongda Chen; Gang Wang; Zhangyan Lyu; Xiaoshuang Feng; Luopei Wei; Xin Li; Yan Wen; Ming Lu; Yuheng Chen; Jufang Shi; Jiansong Ren; Chunqing Lin; Xinyang Yu; Shuohua Chen; Shouling Wu; Ni Li; Min Dai; Jie He
Journal:  Cancer Med       Date:  2019-11-26       Impact factor: 4.452

8.  Development and validation of a nomogram for predicting prostate cancer in patients with PSA ≤ 20 ng/mL at initial biopsy.

Authors:  Qiang Wu; Fanglong Li; Xiaotao Yin; Jiangping Gao; Xu Zhang
Journal:  Medicine (Baltimore)       Date:  2021-12-17       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.